phase II clinical study
Immuneering Partners with Regeneron to Study Combined MEK, PD-1 Inhibitor Therapy in Solid Tumors
Regeneron will supply Libtayo within an ongoing Phase II trial of Immuneering's MEK inhibitor.
Maze Therapeutics Doses First Patient in Phase II APOL1 Inhibitor Kidney Disease Trial
Within the open-label basket trial, patients with two copies of one of two high-risk APOL1 gene variants will receive MZE829.
RedHill Biopharma's Opaganib Enters Phase II Trial With Nubeqa in Select Prostate Cancer Patients
Researchers will use a lipidomic biomarker test to select patients with a poor prognosis who may benefit from an investigational combination therapy.
UniQure Testing Higher Gene Therapy Dose in Phase I/II Fabry Disease Trial
The firm will begin testing a second dose cohort with AMT-191 after receiving a positive recommendation from a data monitoring committee.
UniQure Testing Higher Gene Therapy Dose in Phase I/II SOD1-ALS Trial
With permission from a data safety monitoring committee, the firm will begin treating a second cohort with AMT-162 in the EPISOD1 trial in early 2025.